8-K: Reviva Pharmaceuticals to Restate Financials Due to Accounting Errors

Reviva Pharmaceuticals announced it will restate its financial statements for fiscal year 2022 and interim periods in 2022 and 2023 due to errors in recognizing research and development expenses.

Summary

• Reviva Pharmaceuticals has identified errors in its previously issued financial statements for the fiscal year ended December 31, 2022, and the interim periods of 2022 and 2023.
• The errors primarily relate to the timing of recognition of certain research and development expenses, specifically clinical trial expenses.
• The company failed to properly accrue for clinical trial expenses that were incurred but not yet invoiced, leading to an understatement of expenses.
• The 2022 financial statements understated research and development expenses by approximately $3.9 million.
• This also impacted the total operating expenses, loss from operations, and net loss for 2022, each being understated by approximately $3.9 million.
• The company attributes these errors to material weaknesses in its internal control over financial reporting and clinical trial expenses.
• The company will restate its financial statements in its upcoming 2023 Form 10-K.
• Investors should not rely on previously released financial statements, press releases, earnings releases, investor presentations, or other financial information covering the restatement periods.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials, material weaknesses in internal controls, and the delay in filing the 2023 Form 10-K. These issues raise concerns about the company's financial management and reporting.

Positives

• The company has identified the errors and is taking steps to correct them.
• The company is working to improve its internal controls over financial reporting.
• The company expects to complete the restatement and file its 2023 Form 10-K within the extended filing period.

Negatives

• The company's previously issued financial statements for 2022 and interim periods of 2022 and 2023 are unreliable.
• There were material weaknesses in the company's internal control over financial reporting.
• The company understated research and development expenses by approximately $3.9 million in 2022.
• The company failed to properly review and evaluate progress of expenses incurred in clinical trial contracts.

Risks

• The final adjustments to the financial statements may vary from the estimated amounts and could be material.
• There is a risk of delays in filing the required periodic reports.
• The company may face adverse effects on its business due to the disclosures made in this report.
• The company's stock price may experience volatility.
• There is a risk that the company may need to restate financial results for other accounting issues.

Future Outlook

The company expects to complete the restatement and file its 2023 Form 10-K within the 12b-25 extension period. The company is also working to remediate the material weaknesses in its internal control over financial reporting.

Management Comments

• Management and the Committee have concluded that the Company previously excluded certain clinical trial expenses and associated accruals from the appropriate periods.
• Management determined that any misstatements to the quarterly periods ended March 31, 2022 and June 30, 2022 were not material.

Industry Context

This announcement highlights the importance of robust internal controls and accurate financial reporting, particularly in the biotechnology sector where research and development expenses are significant. It is not uncommon for companies, especially those in the clinical trial phase, to face challenges in accurately estimating and accruing for these expenses.

Comparison to Industry Standards

• Many biotech companies, especially those in early clinical stages, face challenges in accurately accounting for R&D expenses due to the complex nature of clinical trials and the timing of invoices.
• Companies like Xencor and BioMarin have also faced similar issues with accounting for clinical trial expenses, leading to restatements in the past.
• The $3.9 million understatement in R&D expenses for Reviva is significant for a company of its size and highlights the need for improved internal controls.
• Compared to industry best practices, Reviva's failure to properly review and evaluate clinical trial expenses indicates a deficiency in its financial close and reporting process.

Stakeholder Impact

• Shareholders will be impacted by the restatement of financial statements and the potential volatility in the stock price.
• Analysts and investors should not rely on previously released financial information.
• The company's reputation may be negatively affected by the disclosure of accounting errors and internal control weaknesses.

Next Steps

• The company will restate its financial statements for the affected periods.
• The company will file its 2023 Form 10-K within the extended filing period.
• The company will remediate the material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

financial restatement, research and development expenses, clinical trial expenses, internal control, material weakness, accounting errors, financial reporting, SEC filing, Form 8-K, Form 10-K